Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Novel Therapies in Acute Lymphoblastic Leukemia.

Phelan KW, Advani AS.

Curr Hematol Malig Rep. 2018 Aug;13(4):289-299. doi: 10.1007/s11899-018-0457-7. Review.

PMID:
30078158
2.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33 positive AML.

Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.

Blood. 2018 Jul 25. pii: blood-2018-03-841171. doi: 10.1182/blood-2018-03-841171. [Epub ahead of print]

PMID:
30045838
3.

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.

PMID:
29407182
4.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM.

Cancer. 2018 Apr 15;124(8):1722-1732. doi: 10.1002/cncr.31249. Epub 2018 Jan 30.

PMID:
29381191
5.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.

Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS.

Blood Cancer J. 2018 Jan 10;8(1):4. doi: 10.1038/s41408-017-0040-9.

6.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS.

Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925. eCollection 2017 Jun 27.

7.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1831-1839. doi: 10.1200/JCO.2017.75.0232. Epub 2017 Dec 18.

PMID:
29252123
8.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.

Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.

9.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S.

Leukemia. 2018 Apr;32(4):952-959. doi: 10.1038/leu.2017.323. Epub 2017 Nov 6.

PMID:
29104287
10.

"MOR" engineering of antibodies in ALL.

Advani AS.

Blood. 2017 Sep 28;130(13):1487-1488. doi: 10.1182/blood-2017-07-797126. No abstract available.

PMID:
28963104
11.

Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.

Saygin C, Papadantonakis N, Cassaday RD, Liedtke M, Fischer K, Dunn T, Patel BJ, Sobecks R, Kalaycio M, Sekeres MA, Mukherjee S, Gerds AT, Hamilton BK, Carraway HE, Advani AS.

Leuk Lymphoma. 2018 Feb;59(2):363-371. doi: 10.1080/10428194.2017.1344842. Epub 2017 Jul 11.

PMID:
28693363
12.

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI.

Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5. Epub 2017 Jul 4.

PMID:
28687420
13.

Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30. No abstract available.

PMID:
28575698
14.

Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.

Kantarjian HM, Vandendries E, Advani AS.

N Engl J Med. 2016 Nov 24;375(21):2100-2101. doi: 10.1056/NEJMc1612040. No abstract available.

PMID:
27959720
15.

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28. Erratum in: Leuk Res. 2017 Aug;59:65.

PMID:
27736729
16.

Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms.

Visconte V, Przychodzen B, Han Y, Nawrocki ST, Thota S, Kelly KR, Patel BJ, Hirsch C, Advani AS, Carraway HE, Sekeres MA, Maciejewski JP, Carew JS.

Leukemia. 2017 Feb;31(2):505-510. doi: 10.1038/leu.2016.295. Epub 2016 Oct 24. No abstract available.

17.

Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Papadantonakis N, Advani AS.

Ther Adv Hematol. 2016 Oct;7(5):252-269. Epub 2016 Jun 29. Review.

18.

Perspectives and Future Directions for Acute Lymphoblastic Leukemia.

Advani AS.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S6-9. doi: 10.1016/j.clml.2016.02.030. No abstract available.

PMID:
27521327
19.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS.

N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.

20.

Human fibroblasts display a differential focal adhesion phenotype relative to chimpanzee.

Advani AS, Chen AY, Babbitt CC.

Evol Med Public Health. 2016 Mar 23;2016(1):110-6. doi: 10.1093/emph/eow010. Print 2016.

21.

When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults.

O'Dwyer KM, Advani AS.

J Clin Oncol. 2016 Feb 20;34(6):533-8. doi: 10.1200/JCO.2015.64.7156. Epub 2015 Dec 23. Review.

PMID:
26700121
22.

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.

Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A, Advani AS, Maciejewski JP, Sekeres MA, Carew JS.

Leukemia. 2016 May;30(5):1190-4. doi: 10.1038/leu.2015.250. Epub 2015 Sep 15. No abstract available.

23.

Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.

Bumma N, Papadantonakis N, Advani AS.

Future Oncol. 2015;11(12):1729-39. doi: 10.2217/fon.15.84. Review.

PMID:
26075441
24.

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

Ai J, Visconte V, Tabarroki A, Hasrouni E, Hamilton BK, Mukherjee S, Kalaycio M, Sobecks R, Advani AS, Sekeres MA, Shetty S, Tiu RV.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):489-95. doi: 10.1016/j.clml.2015.03.017. Epub 2015 Apr 2.

PMID:
25977195
25.

New antibodies for acute lymphocytic leukemia.

Advani AS.

Clin Adv Hematol Oncol. 2014 Aug;12(8):547-9. No abstract available.

PMID:
25356581
26.

SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.

Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR.

Br J Haematol. 2014 Oct;167(2):233-7. doi: 10.1111/bjh.13035. Epub 2014 Jul 18.

27.

Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).

Visconte V, Tabarroki A, Zhang L, Hasrouni E, Gerace C, Frum R, Ai J, Advani AS, Duong HK, Kalaycio M, Saunthararajah Y, Sekeres MA, His ED, Shetty S, Rogers HJ, Tiu RV.

Am J Hematol. 2014 Aug;89(8):862. doi: 10.1002/ajh.23755. Epub 2014 May 16. No abstract available.

28.

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR.

Br J Haematol. 2014 May;165(4):504-9. doi: 10.1111/bjh.12778. Epub 2014 Mar 3.

29.

Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.

Advani AS, Mahfouz RZ, Maciejewski J, Rybicki L, Sekeres M, Tripp B, Kalaycio M, Bates J, Saunthararajah Y.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):172-177.e1. doi: 10.1016/j.clml.2013.10.001. Epub 2013 Nov 11.

PMID:
24332215
30.

New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors.

Advani AS.

Hematology Am Soc Hematol Educ Program. 2013;2013:131-7. doi: 10.1182/asheducation-2013.1.131. Review.

PMID:
24319174
31.

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe CL, Sekeres MA, Advani AS, Kalaycio M, Copelan EA, Saunthararajah Y, Olalla Saad ST, Maciejewski JP, Tiu RV.

Leukemia. 2014 Jan;28(1):78-87. doi: 10.1038/leu.2013.269. Epub 2013 Sep 18.

PMID:
24045501
32.

Novel targeted therapies in acute lymphoblastic leukemia.

Portell CA, Advani AS.

Leuk Lymphoma. 2014 Apr;55(4):737-48. doi: 10.3109/10428194.2013.823493. Epub 2013 Aug 28. Review.

PMID:
23841506
33.

Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.

Wenzell CM, Gallagher EM, Earl M, Yeh JY, Kusick KN, Advani AS, Kalaycio ME, Mukherjee S, Tiu RV, Maciejewski JP, Sekeres MA.

Am J Hematol. 2013 Oct;88(10):906-9. doi: 10.1002/ajh.23530. Epub 2013 Aug 30.

34.

Biology and treatment of acute lymphocytic leukemia in adolescents and young adults.

Advani AS.

Am Soc Clin Oncol Educ Book. 2013:285-9. doi: 10.1200/EdBook_AM.2013.33.285. Review.

35.

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia.

Portell CA, Wenzell CM, Advani AS.

Clin Pharmacol. 2013 Apr 12;5(Suppl 1):5-11. doi: 10.2147/CPAA.S42689. Print 2013.

36.

The treatment of adolescents and young adults with acute lymphoblastic leukemia.

Lukenbill J, Advani AS.

Curr Hematol Malig Rep. 2013 Jun;8(2):91-7. doi: 10.1007/s11899-013-0159-0. Review.

PMID:
23559026
37.

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.

Cortes J, Feldman E, Yee K, Rizzieri D, Advani AS, Charman A, Spruyt R, Toal M, Kantarjian H.

Lancet Oncol. 2013 Apr;14(4):354-62. doi: 10.1016/S1470-2045(13)70037-8. Epub 2013 Feb 28.

38.

When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?

Lazarus HM, Advani AS.

Hematology Am Soc Hematol Educ Program. 2012;2012:382-8. doi: 10.1182/asheducation-2012.1.382. Review.

PMID:
23233608
39.

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP.

Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22.

40.

Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS, Duong HK, Copelan E, Kapur R, Olalla Saad ST, Maciejewski JP, Tiu RV.

PLoS One. 2012;7(8):e43090. doi: 10.1371/journal.pone.0043090. Epub 2012 Aug 15.

41.

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, McMahon J, Makishima H, Szpurka H, Jankowska A, Jerez A, Sekeres MA, Saunthararajah Y, Advani AS, Copelan E, Koseki H, Isono K, Padgett RA, Osman S, Koide K, O'Keefe C, Maciejewski JP, Tiu RV.

Blood. 2012 Oct 18;120(16):3173-86. doi: 10.1182/blood-2012-05-430876. Epub 2012 Jul 23.

42.

Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.

Sun D, Elson P, Liedtke M, Medeiros BC, Earl M, Alizadeh A, Bates J, Sekeres MA, Coutre S, Kalaycio M, Sobecks R, Copelan E, Advani AS.

Am J Hematol. 2012 Oct;87(10):957-60. doi: 10.1002/ajh.23279. Epub 2012 Jun 22.

43.

Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia.

Brady A, Gibson S, Rybicki L, Hsi E, Saunthararajah Y, Sekeres MA, Tiu R, Copelan E, Kalaycio M, Sobecks R, Bates J, Advani AS.

Eur J Haematol. 2012 Oct;89(4):288-93. doi: 10.1111/j.1600-0609.2012.01825.x. Epub 2012 Jul 26.

PMID:
22725130
44.

Antibody therapy for acute lymphoblastic leukemia.

Portell CA, Advani AS.

Curr Hematol Malig Rep. 2012 Jun;7(2):153-9. doi: 10.1007/s11899-012-0120-7. Review.

PMID:
22422550
45.

Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.

Advani AS.

Clin Adv Hematol Oncol. 2011 Oct;9(10):776-7. No abstract available.

PMID:
22252580
46.

Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL).

Advani AS, Gibson S, Douglas E, Diacovo J, Elson P, Kalaycio M, Copelan E, Sekeres M, Sobecks R, Sungren S, Lagoo A, Rizzieri D, Hsi E.

Br J Haematol. 2011 May;153(4):504-7. doi: 10.1111/j.1365-2141.2011.08607.x. Epub 2011 Mar 6.

PMID:
21375525
47.

Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Mohan SR, Advani AS.

J Adolesc Young Adult Oncol. 2011 Mar;1(1):19-24. doi: 10.1089/jayao.2010.0001.

PMID:
26812565
48.

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.

Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A, Kulasekararaj A, Advani AS, Paquette R, List AF, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP.

Blood. 2011 Apr 28;117(17):4552-60. doi: 10.1182/blood-2010-07-295857. Epub 2011 Feb 1.

49.

A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.

Advani AS, Shadman M, Ali-Osman F, Barker A, Rybicki L, Kalaycio M, Sekeres MA, de Castro CM, Diehl LF, Moore JO, Beaven A, Copelan E, Sobecks R, Talea P, Rizzieri DA.

Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):473-6. doi: 10.3816/CLML.2010.n.082.

PMID:
21156465
50.

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.

Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR.

Br J Haematol. 2010 Dec;151(5):430-4.

Supplemental Content

Loading ...
Support Center